Top

Journal of Cancer Survivorship

Published in:

01-03-2007

Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer

Authors: T. Wethal, J. Kjekshus, J. Røislien, T. Ueland, A. K. Andreassen, R. Wergeland, P. Aukrust, S. D. Fosså

Published in: Journal of Cancer Survivorship | Issue 1/2007

Abstract

Objective

Treatment in testicular cancer survivors (TCSs) may be followed by cardiovascular disorders. We have examined whether today’s three treatment modalities are assicated with a biochemical cardiovascular risk profile.

Materials and methods

In this cross sectional study serum inflammatory markers, atherogenic lipoproteins and gonadal hormones were measured in 589 orchiectomized TCSs who have been treated 5–20 years previously. There were 140 patients treated by surgery alone (SURG), 231 who had had infradiaphragmatic radiotherapy alone (RAD), and 218 who had chemotherapy with or without additional surgery (CHEM).

Results

(1) The RAD group had higher levels of high-sensitivity C-reactive protein and soluble CD40 ligand compared to the SURG group. (2) The CHEM group had lower levels of high density lipoprotein cholesterol and an increased apolipoprotein B/apolipoprotein A-1 ratio than the SURG group. The prevalence of metabolic syndrome was higher in the CHEM group than in the SURG group. (3) Hypogonadism was significantly more prevalent in the CHEM than in the SURG group.

Conclusion

Treatment for TC was related to long-term biochemical cardiovascular risk factors by different pathways: Radiation treatment is followed by elevated serum markers of chronic inflammation and endothelial dysfunction, whereas chemotherapy is followed by the development of atherogenic lipid changes and of the metabolic syndrome. This study provides justification for a prospective study of the impact of these treatment modalities on cardiovascular risk in testical cancer survivors. In the interim testicular cancer survivors should monitor cardiovascular risk over time.

Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004). Antiinflammatory properties of HDL. Circulation Research, 95, 764–772.PubMedCrossRef

Basavaraju, S. R., & Easterly, C. E. (2002). Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Medical Physics, 29, 2391–2403.PubMedCrossRef

Beckman, J. A., Thakore, A., Kalinowski, B. H., Harris, J. R., & Creager M. A. (2001). Radiation therapy impairs endothelium-dependent vasodilation in humans. Journal of the American College of Cardiology, 37, 761–765.PubMedCrossRef

Dirix, L. Y., Libura, M., Libura, J., Vermeulen, P. B., De Bruijn, E. A., & van Oosterom, A. T. (1997). In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs, 8, 859–868.PubMedCrossRef

Eliopoulos, A. G., & Young, L. S. (2004) The role of the CD40 pathway in the pathogenesis and treatment of cancer. Current Opinion in Pharmacology, 4, 360–367.PubMedCrossRef

English, K. M., Mandour, O., Steeds, R. P., Diver, M. J., Jones, T. H., & Channer, K. S. (2000). Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal, 21, 890–894.PubMedCrossRef

Erlinger, T. P., Platz, E. A., Rifai, N., & Helzlsouer, K. J. (2004). C-reactive protein and the risk of incident colorectal cancer. JAMA, 291, 585–590.PubMedCrossRef

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001). JAMA, 285, 2486–2497.

Hanks, G. E., Peters, T., & Owen, J. (1992) Seminoma of the testis: long-term beneficial and deleterious results of radiation. International Journal of Radiation Oncology, Biology, Physics, 24, 913–919.PubMed

10.

Haugnes, H. S., Aass, N., Fossa, S. D., Dahl, O., Klepp, O., Wist, E. A., et al. (2007) Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology, 18, 241–248.

11.

Holm, T., Aukrust, P., Andreassen, A. K., Ueland, T., Brosstad, F., Froland, S. S., et al. (2000). Peripheral endothelial dysfunction in heart transplant recipients: Possible role of proinflammatory cytokines. Clinical Transplantation, 14, 218–225.PubMedCrossRef

12.

Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., et al. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. Journal of Clinical Oncology, 21, 1513–1523.PubMedCrossRef

13.

Jurado, J., & Thompson, P. D. (2005). Prevention of coronary artery disease in cancer patients. Pediatr. Blood Cancer, 44, 620–624.PubMedCrossRef

14.

Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005). The metabolic syndrome: Time for critical appraisal. Joint statement from the American Diabetes Association for the Study of Diabetes. Diabetes Care, 28, 2289–2304.PubMedCrossRef

15.

Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Salonen, R., et al. (2003). Sex hormones, inflammation and the metabolic syndrome: A population-based study. European Journal of Endocrinology, 149, 601–608.PubMedCrossRef

16.

Meinardi, M. T., Gietema, J. A., van Veldhuisen. D. J., van der Graaf, W. T. A., de Vries, E. G. E., & Sleijfer, D. T. (2000). Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews, 26, 429–447.PubMedCrossRef

17.

Myers, R. H., Montgomery, D. C., & Vining, G. G. (2002). Generalized linear models: With applications in engineering and the sciences. Wiley series in probability and statistics. The Family of Generalized Linear Models (pp. 169–71). New York: Wiley.

18.

Nord, C., Bjoro, T., Ellingsen, D., Mykletun, A., Dahl, O., Klepp, O., et al. (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology, 44, 322–328.PubMedCrossRef

19.

Nuver, J., Smit, A. J., Sleijfer, D. T., van Gessel, A. I., van Roon, A. M., van der Meer, J., et al. (2004). Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. European Journal of Cancer, 40, 701–706.PubMedCrossRef

20.

Nuver, J., Smit, A. J., van der Meer, J., van den Berg, M. P., van der Graaf, W. T. A., Meinardi, M. T., et al. (2005a). Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. Journal of Clinical Oncology, 23, 9130–9137.PubMedCrossRef

21.

Nuver, J., Smit, A. J., Wolffenbuttel, B. H., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., et al. (2005b). The metabolic syndrome and disturbance in hormone levels in long-term survivors of disseminated testicular cancer. Journal of Clinical Oncology, 23, 3718–3725.PubMedCrossRef

22.

Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O. 3rd, Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Society. Circulation, 107, 499–511.PubMedCrossRef

23.

Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England journal of medicine, 347, 1557–1565.PubMedCrossRef

24.

Rutter, M. K., Meigs, J. B., Sullivan, L. M., D’Agostino, R. B. Sr., & Wilson, P. W. (2004). C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation, 110, 380–385.PubMedCrossRef

25.

Sagstuen, H., Aass, N., Fossa, S. D., Dahl, O., Klepp, O., Wist, E. A., et al. (2005). Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology, 23, 4980–4990.PubMedCrossRef

26.

Schonbeck, U., Varo, N., Libby, P., Buring, J., & Ridker, P. M. (2001). Soluble CD40L and cardiovascular risk in women. Circulation, 104, 2266–2268.PubMed

27.

Tak, P. P., & Firestein, G. S. (2001). NF-kB: a key role in inflammatory diseases. Journal of Clinical Investigation, 107, 7–11.PubMedCrossRef

28.

Testis. Incidence. Counties. Survival. Cancer Registry of Norway; Institute of Population-based Cancer Research, 2001 (Accessed November 15, 2005, at http://www.kreftregisteret.no/frame.htm?forekomst_og_overlevelse_2001/testis/incidence.htm).

29.

Thorsen, L., Nystad, W., Stigum, H., Dahl, O., Klepp, O., Bremnes, R. M., et al. (2005). The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer, 13, 637–646.PubMedCrossRef

30.

Ubbink, J. B., Vermaak, W. J. H., & Bissbort, S. (1991). Rapid high-performance liquid chromatography assay for total homocysteine levels in human serum. Journal of chromatography, 565, 441–446.PubMedCrossRef

31.

van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., & ten Bokkel Huinink, W. W., (2006). Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. Journal of Clinical Oncology, 24, 467–475.PubMedCrossRef

32.

Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism, 84, 3666–3672.PubMedCrossRef

33.

Wallace, A. M., McMahon, A. D., Packard, C. J., Kelly, A., Shepherd, J., Gaw, A., et al. (2001). Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 104, 3052–3056.PubMed

34.

Whincup, P. H., Danesh, J., Walker, M., Lennon, L., Thomson, A., Appleby, P., et al. (2002). von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. European Heart Journal, 23, 1764–1770.PubMedCrossRef

35.

Wirehn, A. B., Tornberg, S., & Carstensen, J. (2005). Serum cholesterol and testicular cancer incidence in 45 000 men followed for 25 years. British Journal of Cancer, 92, 1785–1786.PubMedCrossRef

36.

Zagars, G. K., Ballo, M. T., Lee, A. K., & Strom, S. S. (2004). Mortality after cure of testicular seminoma. Journal of Clinical Oncology, 22, 640–647.PubMedCrossRef

Title: Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer
Authors: T. Wethal
J. Kjekshus
J. Røislien
T. Ueland
A. K. Andreassen
R. Wergeland
P. Aukrust
S. D. Fosså
Publication date: 01-03-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Journal of Cancer Survivorship / Issue 1/2007
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-007-0012-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Age and attachment style impact stress and depressive symptoms among caregivers: a prospective investigation

Optimizing cancer survivorship

Follow-up care for young adult survivors of cancer: lessons from pediatrics

Long term care planning for cancer survivors: a health services research agenda

Cancer-related identity and positive affect in survivors of prostate cancer

Screening practices in cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer